With the development of progressive right ventricular dysfunction, pulmonary arterial hypertension (PAH) is one of the causes of type 2 cardiohepatic syndrome (CHS). Risk assessment, timely and effective management are crucial to improve survival in PAH. Thus, we aimed to evaluate the presence of CHS at diagnosis and its association with prognosis in patients with PAH. One hundred and eighteen consecutive incident patients with PAH between January 2013 and June 2021 were retrospectively included. The presence of CHS was assessed from blood tests taken during diagnostic evaluation and was defined as elevation of at least two of three cholestatic liver parameters; total bilirubin, alkaline phosphatase and gamma-glutamyl transferase. The primary endpoint was all-cause mortality. Patients were followed for a median period of 58 (32-96) months. 23.7% of the patients had CHS at diagnosis. Significantly more patients in CHS (+) group were in intermediate and high-risk categories according to 2015 ESC/ERS guideline, REVEAL 2.0 and REVEAL Lite 2 risk assessment methods ( = .02, .03 and <.001, respectively). The presence of CHS was identified as an independent predictor of mortality (HR: 2.17, 95% CI: 1.03-4.65,  = .03) along with older age (HR: 2.89, 95% CI: 1.50-5.56,  = .001) and higher WHO functional class (HR: 2.57, 95% CI: 1.07-6.22,  = .03). To conclude, presence of CHS at diagnosis in patients with PAH was associated with severe disease and poor prognosis independent of other well known risk factors. As a simple and easy parameter to assess from routinely taken blood tests, CHS should be evaluated in patients with PAH.

Download full-text PDF

Source
http://dx.doi.org/10.1080/00365513.2023.2225778DOI Listing

Publication Analysis

Top Keywords

cardiohepatic syndrome
8
pulmonary arterial
8
arterial hypertension
8
risk assessment
8
presence chs
8
chs diagnosis
8
patients pah
8
patients chs
8
patients
6
chs
5

Similar Publications

: Multi-organ failure (MOF) often complicates advanced heart failure (HF), contributing to a poor prognosis. The Model of End-Stage Liver Disease 3.0 (MELD-3.

View Article and Find Full Text PDF

The Diagnosis and Treatment of Tricuspid Regurgitation.

Dtsch Arztebl Int

August 2024

Department of Cardiology, LMU Klinikum, Ludwig Maximilian University of Munich, Munich, Germany; German Center for Cardiovascular Research (DZHK), Partner Site Munich Heart Alliance, Munich, Germany; Department of Cardiology and Angiology, University Heart Center Freiburg/Bad Krozingen, University Hospital Freiburg, Freiburg, Germany; Department of Cardiac and Vascular Surgery, University Medical Center Mainz, Johannes Gutenberg University of Mainz, Mainz, Germany.

Background: It is estimated that 6% of persons over age 75 have clinically relevant tricuspid regurgitation (TR). This condition carries a high mortality and is of particular interest because of the recent development of new interventional treatments.

Methods: This review is based on publications that were retrieved by a selective search in the PubMed database for randomized controlled trials (RCTs), observational studies, registry studies, expert recommendations, and current international guidelines.

View Article and Find Full Text PDF
Article Synopsis
  • Pulmonary hypertension (PH) can lead to right ventricular (RV) failure and result in congestive hepatopathy (CH), which negatively affects liver function due to blood stasis.
  • Cannabidiol (CBD) shows promise in reducing RV pressure and hypertrophy in rats, suggesting it might help prevent CH linked to RV failure.
  • The study found that CBD treatment improved liver health in rats with MCT-induced PH by reducing liver/body weight ratio, enhancing liver structure, and lowering levels of inflammatory markers.
View Article and Find Full Text PDF

Liver stiffness is associated with right heart dysfunction, cardiohepatic syndrome, and prognosis in pulmonary hypertension.

J Heart Lung Transplant

July 2024

Department of Internal Medicine, Justus-Liebig-University Giessen, Universities of Giessen and Marburg Lung Center (UGMLC), Member of the German Center for Lung Research (DZL), Giessen, Germany. Electronic address:

Background: Pulmonary hypertension (PH) can lead to congestive hepatopathy, known as cardiohepatic syndrome (CHS). Hepatic congestion is associated with increased liver stiffness, which can be quantified using shear wave elastography. We aimed to investigate whether hepatic shear wave elastography detects patients at risk in the early stages of PH.

View Article and Find Full Text PDF

Heart failure (HF) can damage various organs, including the liver, a phenomenon known as "cardiohepatic syndrome." The latter is characterized by liver congestion and hepatic artery hypoperfusion, which can lead to liver damage. In this study, we aimed to assess liver damage quantitatively in chronic HF (CHF) with sound touch elastography (STE).

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!